Wire · opportunities
Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso's OS win
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Major pharmaceutical companies GSK, Roche, and Novartis secured multi-billion dollar deals with Asian biopharmas, while nine midsized drugmakers signed new most favored nation (MFN) pricing agreements with the U.S. government. Akeso's ivonescimab notably showed overall survival benefits over Keytruda in a head-to-head trial, marking a significant clinical breakthrough.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to rethink PD-1 cancer therapies as Akeso's ivonescimab proves survival gains beyond Keytruda in lung cancer, creating urgency in immuno-oncology development. Meanwhile, the MFN agreements signal pricing pressures that will reshape market access strategies for biotech sellers in the US.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics